Cargando…

A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease

BACKGROUND: In preclinical studies, p38⍺ kinase is implicated in Alzheimer’s disease (AD) pathogenesis. In animal models, it mediates impaired synaptic dysfunction in the hippocampus, causing memory deficits, and is involved in amyloid-beta (Aβ) production and tau pathology. METHODS: The REVERSE-SD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prins, Niels D., Harrison, John E., Chu, Hui-May, Blackburn, Kelly, Alam, John J., Scheltens, Philip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157623/ https://www.ncbi.nlm.nih.gov/pubmed/34044875 http://dx.doi.org/10.1186/s13195-021-00843-2

Ejemplares similares

Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration
por: Jiang, Ying, et al.
Publicado: (2022)

Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies
por: Alam, John J., et al.
Publicado: (2023)

Neflamapimod induces vasodilation in resistance mesenteric arteries by inhibiting p38 MAPKα and downstream Hsp27 phosphorylation
por: Pandey, Ajay K., et al.
Publicado: (2022)

An exploratory clinical study of p38α kinase inhibition in Alzheimer's disease
por: Scheltens, Philip, et al.
Publicado: (2018)

A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer's disease and depressive symptoms
por: Bernard, Katy, et al.
Publicado: (2019)

Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study
por: Ringman, John M, et al.
Publicado: (2012)

Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study
por: Scheltens, Philip, et al.
Publicado: (2018)

Treating Alzheimer’s disease with monoclonal antibodies: current status and outlook for the future
por: Prins, Niels D, et al.
Publicado: (2013)

Weight Maintenance with Litramine (IQP-G-002AS): A 24-Week Double-Blind, Randomized, Placebo-Controlled Study
por: Grube, Barbara, et al.
Publicado: (2015)

Once-daily fluticasone furoate 50 mcg in mild-to-moderate asthma: a 24-week placebo-controlled randomized trial
por: Busse, W W, et al.
Publicado: (2014)

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer's Disease
por: Nakamura, Yu, et al.
Publicado: (2011)

Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD—VIVIAD
por: Vijverberg, E. G. B., et al.
Publicado: (2021)

Efficacy of an Alpha-Blocker for the Treatment of Nonneurogenic Voiding Dysfunction in Women: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial
por: Lee, Young-Suk, et al.
Publicado: (2018)

Add-on treatment with N-acetylcysteine for bipolar depression: a 24-week randomized double-blind parallel group placebo-controlled multicentre trial (NACOS-study protocol)
por: Ellegaard, Pernille Kempel, et al.
Publicado: (2018)

Protocol and Rationale: A 24-week Double-blind, Randomized, Placebo Controlled Trial of the Efficacy of Adjunctive Garcinia mangostana Linn. (Mangosteen) Pericarp for Schizophrenia
por: Turner, Alyna, et al.
Publicado: (2019)

A 12 week, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of HT083 on mild osteoarthritis
por: Lee, Donghun, et al.
Publicado: (2020)

A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia
por: Xiao, Shifu, et al.
Publicado: (2021)

Effect of Probiotic Bifidobacterium breve in Improving Cognitive Function and Preventing Brain Atrophy in Older Patients with Suspected Mild Cognitive Impairment: Results of a 24-Week Randomized, Double-Blind, Placebo-Controlled Trial
por: Asaoka, Daisuke, et al.
Publicado: (2022)

Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes: A 24-week, randomized, double-blind, placebo-controlled trial
por: Häring, Hans-Ulrich, et al.
Publicado: (2013)

Efficacy and Safety of Lipase Inhibitor Orlistat in Japanese with Excessive Visceral Fat Accumulation: 24-Week, Double-Blind, Randomized, Placebo-Controlled Study
por: Shirai, Kohji, et al.
Publicado: (2018)

Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)
por: Aisen, Paul S., et al.
Publicado: (2011)

First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease
por: Ferrero, James, et al.
Publicado: (2016)

Effects of 12 Weeks Cosmos caudatus Supplement among Older Adults with Mild Cognitive Impairment: A Randomized, Double-Blind and Placebo-Controlled Trial
por: You, Yee Xing, et al.
Publicado: (2021)

Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial
por: Price, Joan T, et al.
Publicado: (2021)

Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging
por: Leijenaar, Jolien F., et al.
Publicado: (2017)

NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease
por: Lawlor, Brian, et al.
Publicado: (2014)

Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension
por: Cefalu, William T., et al.
Publicado: (2015)

Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
por: Zhang, Hongyan, et al.
Publicado: (2016)

A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis
por: Allanore, Yannick, et al.
Publicado: (2020)

LBODP044 Effects Of Dietary Supplementation On Progression To Type 2 Diabetes Single Center Randomized Double-blind Placebo-controlled Trial An Interim Analysis At 24 Weeks
por: Chattieng, Preeyapat, et al.
Publicado: (2022)

Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naive Type 2 Diabetic Patients After 24 Weeks of Treatment: Results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1)
por: Raz, Itamar, et al.
Publicado: (2012)

Efficacy and Safety of Lobeglitazone Monotherapy in Patients with Type 2 Diabetes Mellitus over 24-Weeks: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial
por: Kim, Sin Gon, et al.
Publicado: (2014)

Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
por: Landewé, R, et al.
Publicado: (2014)

Efficacy and safety of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24‐week, randomized, double‐blind, placebo‐controlled trial
por: Kadowaki, Takashi, et al.
Publicado: (2017)

Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24‐week, randomized, double‐blind, placebo‐controlled, dose‐ranging phase 2b trial
por: Dubourg, Julie, et al.
Publicado: (2021)

Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium
por: Vogelmeier, Claus, et al.
Publicado: (2010)

Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19
por: Bosaeed, Mohammad, et al.
Publicado: (2021)

Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial
por: Dubée, Vincent, et al.
Publicado: (2021)

A randomized, 4-week double-blind placebo control study on the efficacy of donepezil augmentation of lithium for treatment of acute mania
por: Chen, Jing, et al.
Publicado: (2013)

Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial
por: Henderson, Samuel T, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_h5q88q70a2kfso0c6k7fm9haju